recruit and accumulate in the lung in response to type 2 inflammation. This coincides with production of IL-5 and IL-13 from ILC2s and pulmonary eosinophilia. Although ILC2s have been shown to modulate eosinophil activities, the role of eosinophils in regulating ILC2 responses is less well defined and may represent a novel regulatory feedback pathway. METHODS: Type 2 pulmonary inflammation was induced by either intratracheal cytokine administration (e.g., IL-33) or using models of ovalbumin or house dust mite allergen sensitization/challenge. Eosinophils were specifically depleted immediately prior to instillation or challenge using inducible eosinophil-deficient mice (iPHIL) mice to determine the role of eosinophils on pulmonary ILC2s in these type 2 inflammation models. Lung-derived ILC2s were cultured with eosinophils to define ILC2 and eosinophil interactions. Activation and chemotaxis of ILC2s were assessed in vitro. RESULTS: Depletion of eosinophils in all type 2 models of respiratory inflammation resulted in a significant reduction of total and activated pulmonary ILC2s. For example, lung IL-13 + ILC2s were significantly reduced in IL-33 treated eosinophil-depleted iPHIL mice (236,0186 42,307 vs 106,220 626,617 IL-13 + ILC2s (p<0.05)). Baseline and saline treated animals had comparable pulmonary ILC2 numbers (<20,000 ILC2s (p>0.05) between eosinophil-proficient and deficient mice. In vitro IL-33 activated eosinophils released chemotactic factors for ILC2s and induced activation of ILC2s through cell-cell contact. CONCLUSIONS: Our data demonstrates an underappreciated and significant role for eosinophils in recruitment and activation of ILC2s. These data suggest a reciprocal role for eosinophil-ILC2 interactions in amplification of the type 2 pulmonary inflammatory response.
